Cayston
Drug
Gilead Sciences Inc
Total Payments
$3.3M
Transactions
2,396
Doctors
349
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $12,602 | 3 | 0 |
| 2023 | $175,725 | 8 | 1 |
| 2022 | $97,424 | 154 | 118 |
| 2021 | $242,348 | 87 | 13 |
| 2020 | $496,883 | 194 | 31 |
| 2019 | $582,719 | 545 | 130 |
| 2018 | $907,234 | 663 | 115 |
| 2017 | $777,563 | 742 | 119 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 506 | 71.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $541,515 | 208 | 16.4% |
| Travel and Lodging | $191,299 | 517 | 5.8% |
| Consulting Fee | $156,219 | 72 | 4.7% |
| Food and Beverage | $62,240 | 1,086 | 1.9% |
| Education | $76.38 | 7 | 0.0% |
Payments by Type
Research
$2.3M
506 transactions
General
$951,350
1,890 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study | Gilead Sciences, Inc. | $658,604 | 0 |
| Tobramycin-azithromycin antagonism during cystic fibrosis infections | Gilead Sciences, Inc. | $354,602 | 0 |
| Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization | Gilead Sciences, Inc. | $274,467 | 0 |
| Analysis of inhaled aztreonam study outcomes using multidimensional clinical phenotyping. | Gilead Sciences, Inc. | $175,000 | 0 |
| Long term effects of chronic macrolide therapy and interaction with inhaled antibiotics | Gilead Sciences, Inc. | $163,241 | 0 |
| A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5] | Gilead Sciences Inc | $160,337 | 0 |
| Ultrasensitive detection of reductions in CF airway inflammation | Gilead Sciences, Inc. | $110,583 | 0 |
| Genomic analysis of isolates evolved during antibiotic selection in Cystic Fibrosis | Gilead Sciences Inc | $90,000 | 0 |
| Analysis of inhaled aztreonam study outcomes using multidimensional clinical phenotyping. | Gilead Sciences Inc | $75,000 | 0 |
| A Prospective, 5-year Registry Study to Monitor the Susceptibility to Aztreonam of Pseudomonas aeruginosa (PA) Isolates from Patients with Cystic Fibrosis in the United States [AIR-CF5] | Gilead Sciences, Inc. | $53,649 | 0 |
| Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization | Gilead Sciences Inc | $52,221 | 0 |
| Inflection Point in the Course of FEV1/FVC Ratio over Time in Patients with Cystic Fibrosis: Validation of New Outcome Measures and their Application in Comparative Effectiveness Study of Inhaled Aztreonam and Tobramycin | Gilead Sciences, Inc. | $42,576 | 0 |
| Genomic analysis of isolates evolved during antibiotic selection in Cystic Fibrosis | Gilead Sciences, Inc. | $31,000 | 0 |
| Ultrasensitive detection of reductions in CF airway inflammation | Gilead Sciences Inc | $27,645 | 0 |
| A-PACT: The use of Inhaled Aztreonam to eliminate or decrease the bacterial burden of Pseudomonas Aeruginosa in Children with a Tracheostomy tube. | Gilead Sciences Inc | $21,633 | 0 |
| Impact of a Pharmacist-Directed Comprehensive Medication Management Service on Outcomes of Patients with CF | Gilead Sciences Inc | $20,000 | 0 |
| Aztreonam aerosol to treat cystic fibrosis nasal disease | Gilead Sciences, Inc. | $15,000 | 0 |
| Impact of a Pharmacist-Directed Comprehensive Medication Management Service on Outcomes of Patients with CF | Gilead Sciences, Inc. | $12,975 | 0 |
| A Phase 3, Double Blinded, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solutions in Subjects with Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX1) | Gilead Sciences Inc | $2,617 | 0 |
Top Doctors Receiving Payments for Cayston
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Monica Cardenas | — | Miami, FL | $2.3M | 507 |
| , MD | Pulmonary Disease | Chicago, IL | $89,240 | 132 |
| , M.D | Pulmonary Disease | Baltimore, MD | $82,107 | 74 |
| , M.D | Pediatric Pulmonology | San Diego, CA | $72,996 | 100 |
| , MD PHD | Pediatric Allergy/Immunology | College Station, TX | $71,977 | 98 |
| , M.D | Pediatric Pulmonology | Long Branch, NJ | $66,810 | 84 |
| , MD | Pulmonary Disease | Morristown, NJ | $66,249 | 93 |
| , MD | Pediatric Pulmonology | Austin, TX | $58,740 | 89 |
| , MD | Pulmonary Disease | Dallas, TX | $56,274 | 88 |
| , M.D | Pediatric Pulmonology | Chattanooga, TN | $40,333 | 58 |
| , M.D | Pulmonary Disease | Los Angeles, CA | $34,587 | 55 |
| , MD | Pediatric Pulmonology | Las Vegas, NV | $32,629 | 54 |
| , MD | Internal Medicine | Cleveland, OH | $27,703 | 36 |
| , M.D | Pulmonary Disease | Tampa, FL | $21,308 | 26 |
| Joan Decelie-Germana | Pediatrics | Great Neck, NY | $17,381 | 27 |
| , MD | Internal Medicine | Baltimore, MD | $17,219 | 25 |
| , M.D | Pediatric Pulmonology | Boston, MA | $15,855 | 12 |
| , MD | Pediatric Pulmonology | Wauwatosa, WI | $13,771 | 21 |
| , MD | Pediatric Pulmonology | Austin, TX | $12,218 | 22 |
| , M.D | Pulmonary Disease | New York, NY | $8,629 | 15 |
| , M.D | Pulmonary Disease | Houston, TX | $7,873 | 21 |
| , MB BCH | Pediatrics | Ann Arbor, MI | $5,970 | 12 |
| , MD | Pediatrics | Saint Louis, MO | $4,811 | 7 |
| , MD | Pulmonary Disease | Saint Louis, MO | $4,141 | 11 |
| , MD | Pediatric Pulmonology | Iowa City, IA | $4,006 | 9 |
Ad
Manufacturing Companies
- Gilead Sciences, Inc. $2.5M
- Gilead Sciences Inc $777,563
Product Information
- Type Drug
- Total Payments $3.3M
- Total Doctors 349
- Transactions 2,396
About Cayston
Cayston is a drug associated with $3.3M in payments to 349 healthcare providers, recorded across 2,396 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $12,602 was paid across 3 transactions to 0 doctors.
The most common payment nature for Cayston is "Unspecified" ($2.3M, 71.1% of total).
Cayston is associated with 19 research studies, including "Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study" ($658,604).